Bispecific Antibodies

EHR Implementation of Bispecific Agents for Multiple Myeloma
Multiple Myeloma Education
EHR Implementation of Bispecific Agents for Multiple Myeloma
By Laura R. Bobolts, PharmD, BCOP; Kristen Boykin, PharmD, RPh/CPh, BCOP, BCPS; Hakan Kaya, MD; Lisa Raff, PharmD, MSPharm, BCPS, BCOP; Yonatan Resnick, PharmD
Interview with the Innovators, Multiple Myeloma, Bispecific Antibodies
Videos
In this eighth installment, Kristen Boykin, PharmD, RPh/CPh, BCOP, BCPS, and Yonatan Resnick, PharmD, discuss considerations for preparing a healthcare center’s electronic health record to accommodate bispecific agents in multiple myeloma treatment.
Read More
Total Cost of Care for Bispecific Agents in Multiple Myeloma
Multiple Myeloma Education
Total Cost of Care for Bispecific Agents in Multiple Myeloma
By Laura R. Bobolts, PharmD, BCOP; Kristen Boykin, PharmD, RPh/CPh, BCOP, BCPS; Hakan Kaya, MD; Lisa Raff, PharmD, MSPharm, BCPS, BCOP; Yonatan Resnick, PharmD
Interview with the Innovators, Bispecific Antibodies
Videos
In this seventh installment, Lisa Raff, PharmD, MSPharm, BCPS, BCOP, and Laura Bobolts, PharmD, BCOP, discuss total cost of care associated with bispecific agents and other multiple myeloma treatments, as well as how that compares to the outcomes being produced.
Read More
Payer Policy Development for Bispecific Agents in Multiple Myeloma
Multiple Myeloma Education
Payer Policy Development for Bispecific Agents in Multiple Myeloma
By Laura R. Bobolts, PharmD, BCOP; Kristen Boykin, PharmD, RPh/CPh, BCOP, BCPS; Hakan Kaya, MD; Lisa Raff, PharmD, MSPharm, BCPS, BCOP; Yonatan Resnick, PharmD
Interview with the Innovators, Bispecific Antibodies
Videos

In this fifth installment, Laura R. Bobolts, PharmD, BCOP, and Lisa Raff, MSPharm, BCPS, BCOP, discuss payer considerations when considering reimbursement and formulary inclusion of bispecific agents, as well as how payers keep up-to-date on the evolving landscape of multiple myeloma learning opportunities from bispecific therapy REMS programs.

Read More
Team Education for Bispecific Usage in Multiple Myeloma
Multiple Myeloma Education
Team Education for Bispecific Usage in Multiple Myeloma
By Laura R. Bobolts, PharmD, BCOP; Kristen Boykin, PharmD, RPh/CPh, BCOP, BCPS; Hakan Kaya, MD; Lisa Raff, PharmD, MSPharm, BCPS, BCOP; Yonatan Resnick, PharmD
Interview with the Innovators, Bispecific Antibodies
Videos

In this second installment, Hakan Kaya, MD, and Yonatan Resnick, PharmD, discuss staff educational needs and experiences implementing staff education for bispecific agents in multiple myeloma.

Read More
FDA Granted Second Approval for Epkinly to Treat Patients With Relapsed or Refractory Follicular Lymphoma
FDA Approvals, News & Updates, Lymphoma, Bispecific Antibodies
Web Exclusives
On June 26, 2024, the FDA approved epcoritamab-bysp (Epkinly; Abbvie and Genmab) as the first and only T-cell engaging bispecific antibody administered subcutaneously for the treatment of adults with relapsed or refractory follicular lymphoma (FL) after ≥2 lines of prior therapy.
Read More
Rybrevant First FDA-Approved Therapy for NSCLC with EGFR Exon 20 Insertion Mutations
FDA Approvals, News & Updates, Lung Cancer, Bispecific Antibodies
June 2021, Vol 12, No 3
On May 21, 2021, the FDA accelerated the approval of amivantamab-vmjw (Rybrevant; Janssen/Johnson & Johnson), a bispecific antibody targeting mutations in the EGFR and MET pathways, for adults with non–small-cell lung cancer (NSCLC) that is associated with EGFR exon 20 insertion mutations, as detected by the FDA-approved Guardant360 CDx test, which was approved on the same day as a companion diagnostic for amivantamab. The FDA had granted amivantamab a breakthrough therapy designation for this indication.
Read More
Bispecific Antibodies in Phase 1 Studies Show Promising Efficacy in Heavily Pretreated Patients with Multiple Myeloma
By Wayne Kuznar
Multiple Myeloma, Bispecific Antibodies
February 2021, Vol 12, No 1
Bispecific antibodies are showing promise in patients with hematologic malignancies, notably relapsed or refractory multiple myeloma. Results from studies of 3 bispecific antibodies were presented at ASH 2020, showing deep and durable responses.
Read More

Stay In The Know

Stay up to date on the matters of value in cancer by signing up for the free, bi-monthly VBCC print publication and VBCC weekly e‑newsletter.

Subscribe
Amplity
© Amplity, Inc. All Rights Reserved. Privacy Policy.

We Value Your Feedback! Tell Us How You Consume Content

Your feedback will help us tailor our content to better meet your needs and preferences.

*First Name
*Last Name
*Email
*What's your favorite format for experiencing our content?